1. at the time of randomization, classified as critical (life-threatening) disease 2. subjects currently receiving any other investigational drug, as part of a clinical trial or under emergency approval for sars-cov-2 3. subjects who are known asthmatic patients or hiv-positive 4. subjects who are currently receiving inhaled biologics or anti-viral agents 5. subjects with severe sepsis due to either their sars-cov-2 infection or a concurrent viral, bacterial, or fungal infection with vital organ failure or required vasopressors to maintain blood pressure 6. subjects with alanine aminotransferase (alt), aspartate aminotransferase (ast), or alkaline phosphatase (alp) ≥3x uln and total bilirubin (tbili) ≥2xuln 7. female subjects breastfeeding or planning to breastfeed at any time through 30 days after the last dose of study drug. 8. psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect subject safety and/or compliance. 9. subjects with known hypersensitivity to das181 and/or any of its components.

1. at the time of randomization, classified as critical (life-threatening) disease 2. subjects currently receiving any other investigational drug, as part of a clinical trial or under emergency approval for sars-cov-2 3. subjects who are known asthmatic patients or hiv-positive 4. subjects who are currently receiving inhaled biologics or anti-viral agents 5. subjects with severe sepsis due to either their sars-cov-2 infection or a concurrent viral, bacterial, or fungal infection with vital organ failure or required vasopressors to maintain blood pressure 6. subjects with alanine aminotransferase (alt), aspartate aminotransferase (ast), or alkaline phosphatase (alp) ≥3x uln and total bilirubin (tbili) ≥2xuln 7. female subjects breastfeeding or planning to breastfeed at any time through 30 days after the last dose of study drug. 8. psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect subject safety and/or compliance. 9. subjects with known hypersensitivity to das181 and/or any of its components.

at the time of randomization, classified as critical (life-threatening) disease subjects currently receiving any other investigational drug, as part of a clinical trial or under emergency approval for sars-cov-2 subjects who are known asthmatic patients or hiv-positive subjects who are currently receiving inhaled biologics or anti-viral agents subjects with severe sepsis due to either their sars-cov-2 infection or a concurrent viral, bacterial, or fungal infection with vital organ failure or required vasopressors to maintain blood pressure subjects with alanine aminotransferase (alt), aspartate aminotransferase (ast), or alkaline phosphatase (alp) ≥3x uln and total bilirubin (tbili) ≥2xuln female subjects breastfeeding or planning to breastfeed at any time through 30 days after the last dose of study drug. psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect subject safety and/or compliance. subjects with known hypersensitivity to das181 and/or any of its components.

at the time of randomization, classified as critical (life-threatening) disease subjects currently receiving any other investigational drug, as part of a clinical trial or under emergency approval for sars-cov-2 subjects who are known asthmatic patients or hiv-positive subjects who are currently receiving inhaled biologics or anti-viral agents subjects with severe sepsis due to either their sars-cov-2 infection or a concurrent viral, bacterial, or fungal infection with vital organ failure or required vasopressors to maintain blood pressure subjects with alanine aminotransferase (alt), aspartate aminotransferase (ast), or alkaline phosphatase (alp) ≥3x uln and total bilirubin (tbili) ≥2xuln female subjects breastfeeding or planning to breastfeed at any time through 30 days after the last dose of study drug. psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect subject safety and/or compliance. subjects with known hypersensitivity to das181 and/or any of its components.

1. at the time of randomization, classified as critical (life-threatening) disease 2. subjects currently receiving any other investigational drug, as part of a clinical trial or under emergency approval for sars-cov-2 3. subjects who are known asthmatic patients or hiv-positive 4. subjects who are currently receiving inhaled biologics or anti-viral agents 5. subjects with severe sepsis due to either their sars-cov-2 infection or a concurrent viral, bacterial, or fungal infection with vital organ failure or required vasopressors to maintain blood pressure 6. subjects with alanine aminotransferase (alt), aspartate aminotransferase (ast), or alkaline phosphatase (alp) ≥3x uln and total bilirubin (tbili) ≥2xuln 7. female subjects breastfeeding or planning to breastfeed at any time through 30 days after the last dose of study drug. 8. psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect subject safety and/or compliance. 9. subjects with known hypersensitivity to das181 and/or any of its components.

1. at the time of randomization, classified as critical (life-threatening) disease 2. subjects currently receiving any other investigational drug, as part of a clinical trial or under emergency approval for sars-cov-2 3. subjects who are known asthmatic patients or hiv-positive 4. subjects who are currently receiving inhaled biologics or anti-viral agents 5. subjects with severe sepsis due to either their sars-cov-2 infection or a concurrent viral, bacterial, or fungal infection with vital organ failure or required vasopressors to maintain blood pressure 6. subjects with alanine aminotransferase (alt), aspartate aminotransferase (ast), or alkaline phosphatase (alp) ≥3x uln and total bilirubin (tbili) ≥2xuln 7. female subjects breastfeeding or planning to breastfeed at any time through 30 days after the last dose of study drug. 8. psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect subject safety and/or compliance. 9. subjects with known hypersensitivity to das181 and/or any of its components.